Jiuyuan Gene Engineering

Hangzhou Jiuyuan Gene Engineering is a leading Chinese biopharmaceutical company specializing in the development, manufacturing, and commercialization of recombinant protein and peptide-based therapeutics. Founded in 1993, the company gained prominence by launching China's first recombinant human granulocyte colony-stimulating factor (rhG-CSF) product, Jilifen. Its current portfolio focuses on high-growth therapeutic areas including oncology, metabolic diseases, orthopedics, and hematology. Jiuyuan Gene is notably advancing a robust pipeline of GLP-1 receptor agonists, including a semaglutide biosimilar (JY022) and a dual GIP/GLP-1 receptor agonist. The company operates large-scale GMP manufacturing facilities and is a major player in the Chinese biologics market, recently seeking a public listing on the Hong Kong Stock Exchange.